{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:19:07Z","timestamp":1787163547624,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004637","name":"Nanchang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.intimp.2025.115443","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T08:50:26Z","timestamp":1756543826000},"page":"115443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["GLP-1\/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis"],"prefix":"10.1016","volume":"165","author":[{"given":"Ruixue","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hurong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JPD-212922","article-title":"Preventing Parkinson\u2019s disease: an environmental agenda","volume":"12","author":"De Miranda","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"10423","key":"10.1016\/j.intimp.2025.115443_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2025.115443_bb0015","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s11064-023-03904-0","article-title":"Mitochondrial dysfunction and Parkinson\u2019s disease: pathogenesis and therapeutic strategies","volume":"48","author":"Moradi Vastegani","year":"2023","journal-title":"Neurochem. Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115443_bb0020","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00041.2021","article-title":"Mitochondrial quality control in health and in Parkinson\u2019s disease","volume":"102","author":"Eldeeb","year":"2022","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2025.115443_bb0025","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson\u2019s disease: a promising direction of therapeutic strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41392-022-00933-z","article-title":"PINK1-mediated Drp1(S616) phosphorylation modulates synaptic development and plasticity via promoting mitochondrial fission","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2025.115443_bb0035","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106868","article-title":"IFN-beta rescues neurodegeneration by regulating mitochondrial fission via STAT5, PGAM5, and Drp1","volume":"40","author":"Tresse","year":"2021","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.intimp.2025.115443_bb0040","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41556-021-00798-4","article-title":"MIROs and DRP1 drive mitochondrial-derived vesicle biogenesis and promote quality control","volume":"23","author":"Konig","year":"2021","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115443_bb0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115443_bb0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","article-title":"Dual GLP-1 and GIP agonist Tirzepatide exerted neuroprotective action in a Parkinson\u2019s disease rat model","volume":"16","author":"Delvadia","year":"2025","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.intimp.2025.115443_bb0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","article-title":"A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson\u2019s disease by reducing chronic inflammation in the brain","volume":"27","author":"Cao","year":"2016","journal-title":"Neuroreport"},{"issue":"5","key":"10.1016\/j.intimp.2025.115443_bb0065","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1007\/s11357-024-01116-0","article-title":"DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease","volume":"46","author":"Yu","year":"2024","journal-title":"Geroscience"},{"key":"10.1016\/j.intimp.2025.115443_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113877","article-title":"GLP-1\/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K\/AKT mediated suppression of oxidative stress","volume":"146","author":"Tian","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115443_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson\u2019s disease: implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.intimp.2025.115443_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176819","article-title":"Experimental models of Parkinson\u2019s disease: challenges and opportunities","volume":"980","author":"Lal","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson\u2019s disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"issue":"10103","key":"10.1016\/j.intimp.2025.115443_bb0090","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115443_bb0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bbi.2020.10.014","article-title":"Probiotic clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson\u2019s disease via gut microbiota-GLP-1 pathway","volume":"91","author":"Sun","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2025.115443_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.115001","article-title":"Lactiplantibacillus plantarum SG5 inhibits neuroinflammation in MPTP-induced PD mice through GLP-1\/PGC-1alpha pathway","volume":"383","author":"Qi","year":"2025","journal-title":"Exp. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115443_bb0105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43587-025-00869-3","article-title":"Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice","volume":"5","author":"Zhang","year":"2025","journal-title":"Nat Aging"},{"issue":"4","key":"10.1016\/j.intimp.2025.115443_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.intimp.2025.115443_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol Metab"},{"issue":"10","key":"10.1016\/j.intimp.2025.115443_bb0120","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/aps.2017.49","article-title":"Reassessment of subacute MPTP-treated mice as animal model of Parkinson\u2019s disease","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2025.115443_bb0125","doi-asserted-by":"crossref","first-page":"1428817","DOI":"10.1155\/2022\/1428817","article-title":"DA5-CH and Semaglutide protect against neurodegeneration and reduce alpha-Synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.intimp.2025.115443_bb0130","article-title":"A dual GLP-1\/GIP receptor agonist is more effective than Liraglutide in the A53T mouse model of Parkinson\u2019s disease","volume":"2023","author":"Zhang","year":"2023","journal-title":"Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.intimp.2025.115443_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/biom14070872","article-title":"Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration","volume":"14","author":"Kopp","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential","volume":"18","author":"Henrich","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"23","key":"10.1016\/j.intimp.2025.115443_bb0145","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1111\/bph.14823","article-title":"Andrographolide alleviates parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1","volume":"176","author":"Geng","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115443_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2025.115443_bb0155","article-title":"Semaglutide protects against 6-OHDA toxicity by enhancing autophagy and inhibiting oxidative stress","volume":"2022","author":"Liu","year":"2022","journal-title":"Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12967-023-04270-9","article-title":"Inhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviates atherosclerosis through the modulation of M1 polarization","volume":"21","author":"Su","year":"2023","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115443_bb0165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12013-024-01245-5","article-title":"Drp1: focus on diseases triggered by the mitochondrial pathway","volume":"82","author":"Sun","year":"2024","journal-title":"Cell Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.intimp.2025.115443_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13024-024-00708-w","article-title":"A partial Drp1 knockout improves autophagy flux independent of mitochondrial function","volume":"19","author":"Fan","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.intimp.2025.115443_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102739","article-title":"ROS-Drp1-mediated mitochondria fission contributes to hippocampal HT22 cell apoptosis induced by silver nanoparticles","volume":"63","author":"Chang","year":"2023","journal-title":"Redox Biol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115443_bb0180","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948686","article-title":"PINK1 phosphorylates Drp1(S616) to regulate mitophagy-independent mitochondrial dynamics","volume":"21","author":"Han","year":"2020","journal-title":"EMBO Rep."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:14:41Z","timestamp":1763046881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925014341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"alternative-id":["S1567576925014341"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115443","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1\/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115443"}}